Optimal clinical pathway for adults with movement disorders
Movement disorders encompass a wide range of different disorders such as Parkinson’s disease, atypical parkinsonian disorders such as multiple system atrophy or progressive supranuclear palsy, Huntington’s disease, ataxia, dystonia and Tourette’s syndrome.
Current care for people with movement disorder is often fragmented and may only address some of their symptoms. The pathway emphasises the fundamental importance of people with movement disorders receiving a timely, correct and well-explained diagnosis. The quality of on-going symptom management and specialist multi-disciplinary care will depend on sufficient staffing and access to multi-disciplinary teams with expertise in movement disorders to ensure that movement disorder patients can maintain their independence for as long as possible and have the best possible quality of life. Parkinson’s and all other neurodegenerative movement disorder conditions are relentlessly progressive. Optimal movement disorder clinical pathways therefore need to acknowledge that many movement disorder patients will have changing needs.
The development of the optimal clinical pathway has been overseen by NNAG and led by the Association of British Neurologists (ABN) movement disorder advisory group. The pathway sets out what good treatment, care and support looks like. A public consultation was held to gather input, views and experience from people with neurological conditions and wider stakeholders.
Download the optimal clinical pathway for adults with movement disorders here.
The development of this pathway was overseen by NNAG, with input from these professional bodies and patient organisations: The Association of British Neurologists, Ataxia UK, Dystonia UK, Huntington’s Disease Association, Multiple System Atrophy Trust, The National Neurosciences Advisory Group, Parkinson’s UK, The Neurological Alliance and Tourettes Action.